Nitazoxanide

Generic Name: Nitazoxanide

Brand Names: Alinia, Busulfex

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₉N_₃O_₅S

CAS Number: 55981-09-4

Unique Ingredient Identifier: SOA12P041N

Background: Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment o...

Indication: 用于治疗隐孢子虫、贾第鞭毛虫、阿米巴原虫引起的原虫性腹泻。

Associated Conditions: Diarrhea caused by Cryptosporidium parvum, Diarrhea caused by Giardia lamblia

Associated Therapies: -

Clinical Trials

Nitazoxanide for Treatment of Cryptosporidium in Children

Phase 3

Not yet recruiting

Conditions: Cryptosporidiosis

Interventions: Drug: Nitazoxanide
Drug: Placebo

First Posted Date: 2024-09-19

Last Posted Date: 2024-11-27

Lead Sponsor: Johns Hopkins Bloomberg School of Public Health

Target Recruit Count: 480

Registration Number: NCT06600711

Nitazoxanide in Patients With Metastatic Colorectal Cancer

Phase 3

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Nitazoxanide

First Posted Date: 2023-09-22

Last Posted Date: 2023-09-22

Lead Sponsor: Tanta University

Target Recruit Count: 60

Registration Number: NCT06049901

Locations: 🇪🇬
Tanta University Hospital, Tanta, El-Gharbia Governorate, Egypt

Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus

Phase 2

Recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Nitazoxanide

First Posted Date: 2023-08-25

Last Posted Date: 2023-08-25

Lead Sponsor: Tanta University

Target Recruit Count: 70

Registration Number: NCT06010992

Locations: 🇪🇬
Faculty of medicine, Tanta University, Tanta, El-Gharbia, Egypt
🇪🇬
Faculty of Medicine, Menoufia University, Shibīn Al Kawm, Menoufia, Egypt

Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers

Not Applicable

Completed

Conditions: Drug Interaction

Interventions: Drug: Nitazoxanide
Drug: Atazanavir/ritonavir

First Posted Date: 2023-01-11

Last Posted Date: 2023-09-13

Lead Sponsor: Obafemi Awolowo University

Target Recruit Count: 17

Registration Number: NCT05680792

Locations: 🇳🇬
Obafemi Awolowo University, Ile-Ife, Osun, Nigeria

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

Phase 1

Completed

Conditions: Renal Impairment
Renal Disease
Kidney Disease

Interventions: Drug: Nitazoxanide

First Posted Date: 2022-05-10

Last Posted Date: 2022-10-28

Lead Sponsor: Genfit

Target Recruit Count: 77

Registration Number: NCT05368935

Locations: 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness

Phase 3

Not yet recruiting

Conditions: COVID-19

Interventions: Drug: Nitazoxanide
Dietary Supplement: Vitamin Super-B Complex
Drug: Placebo
Other: Standard of Care

First Posted Date: 2021-12-14

Last Posted Date: 2023-09-29

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 2000

Registration Number: NCT05157243

Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness

Phase 3

Not yet recruiting

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: Nitazoxanide
Dietary Supplement: Vitamin Super-B Complex

First Posted Date: 2021-12-14

Last Posted Date: 2023-09-29

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 600

Registration Number: NCT05157269

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Phase 1

Completed

Conditions: Moderate Hepatic Impairment
Severe Hepatic Impairment
Liver Diseases

Interventions: Drug: Nitazoxanide

First Posted Date: 2021-11-11

Last Posted Date: 2022-10-14

Lead Sponsor: Genfit

Target Recruit Count: 25

Registration Number: NCT05116826

Locations: 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Phase 2

Recruiting

Conditions: COVID-19

Interventions: Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™)
Drug: Nitazoxanide
Drug: Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)
Drug: Hydroxychloroquine
Other: No treatment
Drug: Monoclonal antibodies
Drug: Fluoxetine
Drug: Molnupiravir
Drug: Sotrovimab
Drug: Ensitrelvir
Drug: Favipiravir
Drug: Ivermectin
Drug: Remdesivir
Drug: Atilotrelvir/ritonavir
Drug: Metformin
Drug: Nirmatrelvir/ritonavir
Drug: Nirmatrelvir

First Posted Date: 2021-09-13

Last Posted Date: 2024-10-28

Lead Sponsor: University of Oxford

Target Recruit Count: 3800

Registration Number: NCT05041907

Locations: 🇳🇵
Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
🇧🇷
Universidade Federal de Minas Gerais, Minas Gerais, Brazil
🇱🇦
Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane, Lao People's Democratic Republic

and more 4 locations

Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19

Phase 2

Completed

Conditions: Covid19

Interventions: Drug: Favipiravir
Other: Nitazoxanide Placebo
Drug: Nitazoxanide

First Posted Date: 2021-06-09

Last Posted Date: 2023-03-24

Lead Sponsor: Coordinación de Investigación en Salud, Mexico

Target Recruit Count: 120

Registration Number: NCT04918927

Locations: 🇲🇽
Hospital de Infectología "Daniel Méndez Hernández" del Centro Médico Nacional La Raza, Ciudad de Mexico, Azcapotzalco, Mexico

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy